Christine Garcia1, Jacqueline Wendt1, Liisa Lyon2, Jennifer Jones3, Ramey D Littell1, Mary Anne Armstrong2, Tina Raine-Bennett4, C Bethan Powell5. 1. Kaiser Permanente Medical Group, Gynecologic Oncology Division, USA. 2. Kaiser Permanente Medical Group, Division of Research, USA. 3. Kaiser Permanente Medical Group, Genetics Department, USA. 4. Kaiser Permanente Medical Group, Women's Health Institute, USA. 5. Kaiser Permanente Medical Group, Gynecologic Oncology Division, USA. Electronic address: Bethan.powell@kp.org.
Abstract
OBJECTIVE: To assess the uptake of risk-reducing options for the management of ovarian and breast cancer risk in BRCA mutation carriers in a large community based integrated health system in Northern California. METHODS: A retrospective cohort of deleterious BRCA mutation carriers (1995-2012) was evaluated for consistency with NCCN guidelines for risk reducing salpingo-oophorectomy (RRSO) by age of 35-40, risk reducing mastectomy (RRM), as well as surveillance practices, including pelvic ultrasound, CA 125, mammogram, and breast MRI. Secondary outcomes included the use of chemoprevention and hormone replacement. RESULTS: Of the 305 eligible women, 170 were BRCA1 positive, and 135 were BRCA2 positive. Seventy four percent underwent RRSO with only 17% under age 40, while 44% underwent RRM. The median time from the test to both RRSO and RRM was 6 months. In the first year after BRCA diagnosis, 45% underwent a pelvic ultrasound, dropping to 2.3% by year 5. In year 1, 47% had a CA 125, dropping to 2% by year 5. The number of women undergoing annual MRI and mammogram fell similarly over time. Sixteen percent of BRCA carriers used oral contraceptives (OCPs) and only one patient used tamoxifen for chemoprevention. CONCLUSION: Uptake of RRSO in BRCA carriers in a population based health system is high, however the majority of women do not have RRSO by the NCCN recommended age. Compliance with surveillance is low and rapidly declines even 1 year out from testing. Attention needs to be focused on the earlier identification of BRCA mutation carriers with consolidated and standardized care to improve risk reduction.
OBJECTIVE: To assess the uptake of risk-reducing options for the management of ovarian and breast cancer risk in BRCA mutation carriers in a large community based integrated health system in Northern California. METHODS: A retrospective cohort of deleterious BRCA mutation carriers (1995-2012) was evaluated for consistency with NCCN guidelines for risk reducing salpingo-oophorectomy (RRSO) by age of 35-40, risk reducing mastectomy (RRM), as well as surveillance practices, including pelvic ultrasound, CA 125, mammogram, and breast MRI. Secondary outcomes included the use of chemoprevention and hormone replacement. RESULTS: Of the 305 eligible women, 170 were BRCA1 positive, and 135 were BRCA2 positive. Seventy four percent underwent RRSO with only 17% under age 40, while 44% underwent RRM. The median time from the test to both RRSO and RRM was 6 months. In the first year after BRCA diagnosis, 45% underwent a pelvic ultrasound, dropping to 2.3% by year 5. In year 1, 47% had a CA 125, dropping to 2% by year 5. The number of women undergoing annual MRI and mammogram fell similarly over time. Sixteen percent of BRCA carriers used oral contraceptives (OCPs) and only one patient used tamoxifen for chemoprevention. CONCLUSION: Uptake of RRSO in BRCA carriers in a population based health system is high, however the majority of women do not have RRSO by the NCCN recommended age. Compliance with surveillance is low and rapidly declines even 1 year out from testing. Attention needs to be focused on the earlier identification of BRCA mutation carriers with consolidated and standardized care to improve risk reduction.
Authors: Deborah Cragun; Anne Weidner; Courtney Lewis; Devon Bonner; Jongphil Kim; Susan T Vadaparampil; Tuya Pal Journal: Cancer Date: 2017-02-09 Impact factor: 6.860
Authors: Xinglei Chai; Tara M Friebel; Christian F Singer; D Gareth Evans; Henry T Lynch; Claudine Isaacs; Judy E Garber; Susan L Neuhausen; Ellen Matloff; Rosalind Eeles; Nadine Tung; Jeffrey N Weitzel; Fergus J Couch; Peter J Hulick; Patricia A Ganz; Mary B Daly; Olufunmilayo I Olopade; Gail Tomlinson; Joanne L Blum; Susan M Domchek; Jinbo Chen; Timothy R Rebbeck Journal: Breast Cancer Res Treat Date: 2014-10-14 Impact factor: 4.872
Authors: Adam H Buchanan; Corrine I Voils; Joellen M Schildkraut; Catherine Fine; Nora K Horick; P Kelly Marcom; Kristi Wiggins; Celette Sugg Skinner Journal: J Genet Couns Date: 2016-06-06 Impact factor: 2.537
Authors: Claire C Conley; Monica L Kasting; Bianca M Augusto; Jennifer D Garcia; Deborah Cragun; Brian D Gonzalez; Jongphil Kim; Kimlin Tam Ashing; Cheryl L Knott; Chanita Hughes-Halbert; Tuya Pal; Susan T Vadaparampil Journal: Ann Surg Oncol Date: 2019-11-01 Impact factor: 5.344